All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Centers for Medicare & Medicaid Services, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 2.5 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Quanterix
All 1 tracked stories fall under one category: medical-devices. Of the tracked stories, 1 of 1 also mention Centers for Medicare & Medicaid Services, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 2.5 for the same window. Their average consequence score of 6 runs above the beat's 5.9 for that window. We currently track 1 Healthcare story that mention Quanterix, all published on March 4, 2026.
Stories tracked
1
Sources per story
6
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Quanterix. Shared-story counts are live from our verified record — not editorial picks.
Quanterix reported a 25% year-over-year revenue increase to $43.9 million in Q4 2025, driven by a surge in diagnostics partner revenue and critical regulatory milestones. The company achieved a commercial breakthrough with a $897 CMS reimbursement rate for its Lucent AD Complete test, positioning it for large-scale clinical adoption.
Quanterix is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.